Clinical takeawayConsider extended antibiotic regimens, oral vancomycin prophylaxis during subsequent systemic antibiotic exposure, and microbiome restoration therapies for patients with CDI, especially those at high risk of recurrence (older adults, immunocompromised individuals, transplant recipients, and patients with IBD), while monitoring for potential adverse events.
What it foundExtended antibiotic regimens, oral vancomycin prophylaxis during systemic antibiotic exposure, and microbiome restoration therapies (e.g., fecal microbiota transplantation or FDA-approved microbiota-based therapies) reduce recurrent Clostridioides difficile infection (rCDI) compared to standard care.
ContextThis review confirms and refines current strategies for preventing CDI and rCDI, emphasizing microbiome preservation and restoration as central to reducing recurrence.